Colon26 Syngeneic Model Overview
The Colon26 syngeneic model is a well-established murine colorectal carcinoma system derived from a spontaneous colon tumor in BALB/c mice. It is one of the most frequently used syngeneic models for immunotherapy, chemotherapy, and combination treatment research. Colon26 tumors grow rapidly and reproducibly in immunocompetent hosts, allowing detailed evaluation of tumor-immune dynamics, checkpoint inhibitor response, and the efficacy of experimental anticancer agents.
Following subcutaneous or orthotopic implantation, Colon26 tumors exhibit aggressive local growth with limited spontaneous metastasis, depending on implantation route and host immune status. The model retains a functional immune environment, making it suitable for studies investigating adaptive immune activation, immune memory formation, and tumor regression following immunomodulatory therapy. Owing to its stability, responsiveness, and translational relevance, the Colon26 model serves as a robust platform for testing immuno-oncology strategies against murine colorectal carcinoma.
Request a Custom Quote for Colon26 Syngeneic ModelBiological and Molecular Characteristics
The Colon26 cell line was derived from a spontaneous colon carcinoma in BALB/c mice and displays epithelial morphology consistent with poorly differentiated adenocarcinoma. The model is receptor-negative for ER, PR, and HER2 and has been characterized by a high mutation rate and elevated expression of immunogenic neoantigens, contributing to its partial sensitivity to immune checkpoint blockade. Colon26 tumors express high levels of inflammatory and angiogenic mediators, including IL-6, TNF-α, and VEGF, which promote immune cell recruitment and vascular development within the tumor microenvironment.
The immune landscape of Colon26 tumors consists of macrophages, dendritic cells, neutrophils, and T lymphocytes in variable proportions, creating a complex interplay of immune activation and suppression. This balance allows the model to recapitulate the immunological heterogeneity observed in clinical colorectal cancer, making it suitable for evaluating both immune stimulatory and cytotoxic regimens.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous colon carcinoma (mouse) |
| Histological type | Poorly differentiated adenocarcinoma |
| Inoculation route | Subcutaneous, orthotopic, or intravenous |
| Tumor take rate | >95% |
| Doubling time | Approximately 2–3 days in vivo |
| Metastatic potential | Low to moderate; lung or liver under certain routes |
| Immunophenotype | Mixed myeloid and T-cell infiltration |
| Common applications | Immunotherapy, chemotherapy, combination therapy development |
In Vivo Model Development and Tumorigenicity
Colon26 tumors are most commonly established by subcutaneous implantation of viable cells into immunocompetent BALB/c mice, resulting in rapid, consistent tumor formation within five to six days post-inoculation. Orthotopic implantation into the cecal wall provides a more physiologic representation of colorectal cancer, often accompanied by limited regional metastasis. Intravenous administration produces disseminated metastases, most frequently within the lungs, and is used for evaluating systemic therapeutic efficacy.
This model’s rapid growth kinetics, high tumor take rate, and predictable morphology make it ideal for short-duration efficacy studies. The immune responsiveness of Colon26 tumors also enables exploration of immunotherapy timing, dosing, and combination effects. Because of its immunocompetent host background, the model is widely utilized to study tumor-immune equilibrium, immunogenic cell death, and the long-term establishment of antitumor immunity.
Request a Custom Quote for Colon26 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histologically, Colon26 tumors are composed of densely packed epithelial cells with high nuclear-to-cytoplasmic ratios, irregular glandular architecture, and frequent mitotic figures. The tumor stroma contains fibroblasts, macrophages, and lymphocytes embedded within a collagenous matrix. Angiogenesis is prominent, with disorganized vasculature and focal necrosis indicative of rapid proliferation.
Immunohistochemical characterization shows strong Ki-67 staining, consistent with rapid cellular turnover. CD3 and CD8 staining confirm extensive T-cell infiltration, particularly in the perivascular and invasive regions. F4/80 and CD11b staining identify macrophage and myeloid-derived cell populations within the stroma, while PD-L1 expression is moderate and inducible by interferon-γ signaling. The overall histopathological and immunological features of Colon26 tumors reflect an immunogenic yet partially suppressive environment, offering an excellent system for evaluating immune-based and chemotherapeutic combinations.
Preclinical Applications and Drug Response
The Colon26 syngeneic model is extensively used for preclinical studies investigating immunotherapies, cytotoxic chemotherapies, and multimodal treatment strategies for colorectal carcinoma. It exhibits partial sensitivity to checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, with therapeutic responses characterized by slowed tumor progression and increased CD8⁺ T-cell activation. The model also demonstrates responsiveness to chemotherapeutic agents such as 5-fluorouracil and oxaliplatin, which can enhance immune priming through the induction of immunogenic cell death.
Colon26 has been a foundational system for combination immunotherapy studies, including those involving cytokine agonists (IL-2, IL-12, GM-CSF), oncolytic viruses, and vaccine-based platforms. The reproducibility of tumor establishment, coupled with measurable immune activation and moderate aggressiveness, makes the Colon26 model an ideal choice for mechanistic studies of immune modulation and translational development of colorectal cancer therapeutics.
Request This Model
To request the Colon26 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for Colon26 Syngeneic Model